首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   53篇
  完全免费   2篇
  药学   55篇
  2019年   1篇
  2018年   1篇
  2017年   2篇
  2015年   2篇
  2014年   5篇
  2013年   4篇
  2012年   5篇
  2011年   2篇
  2010年   2篇
  2009年   5篇
  2007年   3篇
  2006年   3篇
  2005年   4篇
  2004年   5篇
  2003年   1篇
  2002年   1篇
  2001年   1篇
  2000年   2篇
  1995年   2篇
  1984年   1篇
  1979年   1篇
  1976年   1篇
  1975年   1篇
排序方式: 共有55条查询结果,搜索用时 46 毫秒
1.
噻唑烷二酮类不良反应研究进展   总被引:8,自引:0,他引:8  
王振基  申竹芳 《中国新药杂志》2005,14(11):1364-1366
噻唑烷二酮类胰岛素增敏剂通过增加外周组织对胰岛素的敏感性而改善胰岛素抵抗,降低血胰岛素水平、减少胰岛素用量,降低血糖和HbAlc,提高HDL-C水平,保护胰岛β细胞功能;还能对抗多种心血管疾病危险因子的损害,有益于糖尿病大血管和微血管并发症的防治.然而近年来有关噻唑烷二酮类药物不良反应的报道越来越多,部分病人甚至因此而停药.笔者综述噻唑烷二酮类药物不良反应.  相似文献
2.
目的:探讨抗精神病药物(APS)所致体重增加与多巴胺D2受体(DRD2)基因多态性和治疗效应之间有无相关性。方法:采用PCR-RFLP方法分析117例首发精神分裂症患者DRD2基因TaqI A多态性。APS治疗10周,测定患者治疗前后体重和体重指数(BMI),用阳性和阴性症状量表(PANSS)评定患者治疗前后精神症状,并分析基因型和PANSS减分率与BMI变化值的相关性。结果:治疗后患者平均体重增加(3±3)kg或基础体重的(6±6)%,体重变化的范围为-7 kg-12 kg或-7.8%-32.4%;患者年龄和基础BMI明显影响BMI变化值,差异有显著性(P=0.03,P=0.0001);DRD2基因TaqI多态性A1等位基因和PANSS减分率对BMI变化值的影响经检验差异均无显著性(均P>0.05)。结论:DRD2基因TaqI多态性不可能是APS所致体重增加的主要因素;体重增加不作为APS临床治疗效果的预测指标。  相似文献
3.
The effect of the -noradrenergic receptor agonist, clonidine, on food intake and weight was examined in ten adult Stumptail macaque monkeys. An intramuscular injection of 0.1 mg/kg of clonidine HCl for seven consecutive days significantly increased food intake from baseline levels throughout treatment. All but two monkeys gained weight during clonidine treatment with seven animals gaining from 5–15% of their original body weight by the end of 1 week.To whom offprint requests should be sent  相似文献
4.
Weight gain induced by clozapine   总被引:1,自引:0,他引:1  
Patients were investigated to gain more insight into the incidence and time course of clozapine induced weight gain (n = 81) and to compare weight gain in patients treated with clozapine (n = 31) with that of patients treated with standard antipsychotics (haloperidol, n = 11). 35.7% of the patients treated with clozapine gained weight according to our definition. If patients gained weight on clozapine this side effect was apparent within the first 12 weeks of treatment. Deviation from normal body weight at the beginning of treatment showed a significant influence on weight gain. Sex, severity of illness, comedication, mean clozapine dose and degree of improvement did not show an influence on this side effect. Weight increase was significantly higher in patients treated with clozapine than in patients treated with haloperidol.  相似文献
5.
目的 探讨抗精神病药物 (APS)所致体重增加与多巴胺D2 受体 (DRD2 )基因TaqIA多态性和治疗效应之间有无相关。方法 采用PCR RFLP方法分析 117例首发精神分裂症患者DRD2 基因TaqIA多态性 ,APS(氯丙嗪或利培酮 )单药治疗 10周 ,测定患者治疗前后体重和体重指数 (BMI) ,用阳性和阴性症状量表 (PANSS)评定患者治疗前后精神症状 ,并分析BMI变化值与基因型和PANSS减分率的相关性。结果 治疗后患者平均体重变化 (3 15± 3 47)kg或基础体重的(5 6 9± 6 15 ) % ,体重变化的范围为 - 7kg~ 12kg或 - 7 78%~ 32 43% ;患者年龄和基础BMI明显影响BMI变化值 ,差异有显著性 (P =0 0 3)和非常显著性 (P =0 0 0 0 1) ;A1等位基因和PANSS减分率对BMI变化值的影响差异均无显著性 (P >0 0 5 )。结论 DRD2 基因TaqIA多态性不可能是APS所致精神分裂症体重增加的主要遗传因素 ;体重增加不是APS临床治疗效果的指标。  相似文献
6.
超重和肥胖者血清TNF-α、IL-6及CRP与肥胖的关系   总被引:1,自引:0,他引:1  
目的:探讨17~36岁超重和肥胖者炎性指标血清肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)及C-反应蛋白(CRP)与肥胖指标的关系。方法:测量研究对象的体质量、身高及腰围(WC),并计算体质量指数(BMI)和体脂含量百分比(FAT%)。以BMI为依据,把66个研究对象分为超重肥胖组(BMI≥25kg/m^2,0B组)32例,正常对照组(BMI〈25kg/m^2,NOB组)34例。空腹静脉取血,放射免疫法测定血清TNF-α、IL-6水平,快速免疫消浊比浊法测定血清CRP水平。结果:OB组体质量、WC、BMI及FAT%明显高于NOB组(均P〈0.01);血清TNF-α、IL-6、CRP水平较NOB组有升高,但差异均无统计学意义(P〉0.05);3种炎症指标均与WC、BMI及FAT%呈明显正相关(均P〈0.05)。结论:17~36岁超重肥胖者机体可能存在炎症指标的异常,且与肥胖关系密切,提示其机体可能存在一定慢性炎症反应。  相似文献
7.
Rationale  Atypical antipsychotic-induced weight gain is a significant impediment in the treatment of schizophrenia. Objectives  In a putative model of antipsychotic drug-induced weight gain, we investigated the effects of sub-chronic olanzapine on body weight, meal patterns, the expression of genes encoding for hypothalamic feeding-related neuropeptides and the contribution of hyperphagia to olanzapine-induced weight gain in rats. Materials and methods  In experiment 1, female rats received either olanzapine (1 mg/kg, p.o.) or vehicle, twice daily for 7 days, while meal patterns were recorded. At the end of the treatment regimen, we measured the levels of hypothalamic messenger RNAs (mRNAs) encoding neuropeptide-Y (NPY), hypocretin/orexin (HCRT), melanin concentrating hormone and pro-opiomelanocortin. NPY and HCRT mRNA levels were also assessed in a separate cohort of female rats treated acutely with olanzapine (1 mg/kg, p.o.). In experiment 2, we investigated the effect of a pair-feeding paradigm on sub-chronic (1 mg/kg, p.o.) olanzapine-induced weight gain. Results  In experiment 1, sub-chronic olanzapine increased body weight, food intake and meal size. Hypothalamic neuropeptide mRNA levels were unchanged after both acute and sub-chronic olanzapine treatment. In experiment 2, the restriction of food intake to the level of vehicle-treated controls abolished the sub-chronic olanzapine-induced increase in body weight. Conclusions  Hyperphagia mediated by drug-induced impairments in satiety (as evidenced by increased meal size) is a key requirement for olanzapine-induced weight gain in this paradigm. However, olanzapine-induced hyperphagia and weight gain may not be mediated via alterations in the expression of the feeding-related hypothalamic neuropeptides examined in this study.  相似文献
8.
An overview of the safety of sucralose   总被引:1,自引:0,他引:1  
Sucralose is a non-nutritive sweetener used in a broad range of foods and beverages and is the non-nutritive sweetener in retail SPLENDA® Sweetening Products, composed of sucralose and common food ingredients. A review of the extensive body of evidence that supports the safety of sucralose is provided. The results of an independent review of a new study investigating the safety of a sucralose-mixture retail product, Granulated SPLENDA® No Calorie Sweetener, are also discussed. The collective evidence supports the conclusion that the ingredient, sucralose, is safe for use in food and that the sucralose-mixture product, Granulated SPLENDA® No Calorie Sweetener, is also safe for its intended use.  相似文献
9.
抗癫痫药物对体质量指数的影响   总被引:1,自引:1,他引:0  
目的 研究抗癫痫药物对患者体质量指数(BMI)的影响. 方法 收集癫痫患者中BMI>15 kg.(m2-1的患者共74例,比较BMI与患者年龄、所用药物、食欲以及血药浓度的关系. 结果 常用的抗癫痫药物卡马西平、丙戊酸均可导致患者食欲及体质量增加,而且年龄越小越明显. 结论 癫痫患者使用抗癫痫药物时要注意控制食欲和体质量.  相似文献
10.
对拆包装药品在不同存储条件下外观及片重变化的研究   总被引:1,自引:0,他引:1  
研究拆包装药品在不同存储条件下外观和片重的变化,以选择合适的备药品种,为科学备药提供参考。方法:选取住院药房孟鲁司特钠咀嚼片、复方卡比多巴-左旋多巴控释片、瑞格列奈片、溴隐亭片、缬沙坦氢氯噻嗪片、拉西地平片、替米沙坦片、丙戊酸钠缓释片、阿卡波糖片、复方α-酮酸薄膜衣片 10种以往不拆包装备药的口服药,各以带盖摆药杯(药杯组)和LOCK盒(LOCK盒组)为存储方式,观察药片从原包装剥出后0、2、4、8、24 h 5个存储时间点的外观,测定片重差异。结果:药杯组有5种药品外观发生不同程度的变化,而LOCK盒组均未出现明显变化。方差分析结果显示,每种药品在不同测定时间的片重均具有显著差异(P<0.001);药杯组阿卡波糖片24 h片重差异最大,24 h增重率达10.8%,复方卡比多巴-左旋多巴控释片差异最小,24 h增重率为0.5%。孟鲁司特钠咀嚼片、替米沙坦片、阿卡波糖片3种药品在两种存储方式下片重存在显著差异(P<0.001),其他7种药品片重无显著差异(P>0.05);除复方卡比多巴-左旋多巴控释片外,药杯组其他9种药品的24 h增重率均大于LOCK盒组。结论:实验药品中瑞格列奈片、复方卡比多巴-左旋多巴控释片、缬沙坦氢氯噻嗪片、拉西地平片、复方α-酮酸薄膜衣片5种药品以LOCK盒为存储方式,24 h内药品外观和片重是稳定的。  相似文献
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号